There have been some pre-clinical examples of restoration of PC as a therapeutic target, such as restoration of PC by HDAC inhibitors in cholangiocarcinoma reduce cholangiocarcinoma cell growth (41–43). The gene discussed is HDAC9; the disease is cholangiocarcinoma.